These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11857395)

  • 1. Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women.
    Talley LI; Grizzle WE; Waterbor JW; Brown D; Weiss H; Frost AR
    Int J Cancer; 2002 Mar; 98(1):118-27. PubMed ID: 11857395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of estrogen and progesterone receptors in human ductal invasive breast carcinoma not otherwise specified: is there any difference between premenopausal and postmenopausal women?
    Petricević J; Petković M; Jonjić N
    Acta Clin Croat; 2011 Jun; 50(2):169-75. PubMed ID: 22263379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
    Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas.
    Soslow RA; Carlson DL; Horenstein MG; Osborne MP
    Breast Cancer Res Treat; 2000 May; 61(2):161-70. PubMed ID: 10942102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of women with node negative breast cancer in the Auckland region.
    Lethaby AE; Mason BH; Harvey VJ; Holdaway IM
    N Z Med J; 1996 Sep; 109(1029):330-3. PubMed ID: 8862351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.
    Enger SM; Ross RK; Paganini-Hill A; Carpenter CL; Bernstein L
    Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):681-7. PubMed ID: 10919738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The estrogen receptor/progesterone receptor quotient as an index of the transcriptional activity of estrogen receptors in breast cancer].
    Navarro MA; Díez Gibert O; Fernández-Montolí ME; Rosel P; Bonnin MR
    Med Clin (Barc); 1995 May; 104(18):681-2. PubMed ID: 7769876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
    J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Subtypes and Prognostic Factors among Premenopausal and Postmenopausal Thai Women with Invasive Breast Cancer: 15 Years Follow-up Data.
    Tubtimhin S; Promthet S; Suwanrungruang K; Supaattagorn P
    Asian Pac J Cancer Prev; 2018 Nov; 19(11):3167-3174. PubMed ID: 30486605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Estrogen and progesterone receptors of primary breast carcinoma and their axillary lymph node metastases--immunohistochemical investigations of routine formalin-fixed paraffin-embedded tissue].
    Schulze MH; Buchmann J
    Zentralbl Gynakol; 2000; 122(2):92-5. PubMed ID: 10721188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction.
    Ning L; Liu Y; He X; Han R; Xin Y; Zhao J; Liu X
    Am J Clin Oncol; 2024 May; 47(5):228-238. PubMed ID: 38131531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of breast cancer subtypes and body mass index.
    Petekkaya I; Sahin U; Gezgen G; Solak M; Yuce D; Dizdar O; Arslan C; Ayyildiz V; Altundag K
    Tumori; 2013; 99(2):129-33. PubMed ID: 23748802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer.
    Rudolph P; Kühling H; Alm P; Fernö M; Baldetorp B; Olsson H; Parwaresch R
    Int J Cancer; 2003 Jul; 105(5):674-80. PubMed ID: 12740917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer.
    Fuckar D; Dekanić A; Stifter S; Mustać E; Krstulja M; Dobrila F; Jonjić N
    Int J Surg Pathol; 2006 Jan; 14(1):49-55. PubMed ID: 16501835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women.
    Biglia N; Peano E; Sgandurra P; Moggio G; Pecchio S; Maggiorotto F; Sismondi P
    Gynecol Endocrinol; 2013 Mar; 29(3):263-7. PubMed ID: 23174088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
    Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
    J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal receptor determination of 1,052 Chinese breast cancers.
    Chow LW; Ho P
    J Surg Oncol; 2000 Nov; 75(3):172-5. PubMed ID: 11088048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.